Table 1.
Group | Before modeling | 8 wk after modeling | 14 d after medication | 28 d after medication |
---|---|---|---|---|
A | 15.50 ± 1.246 | 16.08 ± 0.975∗∗ | 17.00 ± 0.862∗∗ | 18.42 ± 0.596∗∗∆∆ |
B | 13.83 ± 1.492▲ | 2.92 ± 0.499▲▲ | 3.58 ± 0.557▲▲ | 2.42 ± 0.583▲▲∆∆ |
C | 15.50 ± 1.011▲∗ | 3.42 ± 0.583▲▲∗ | 6.75 ± 0.808▲▲∗∗ | 8.92 ± 0.398▲▲∗∗∆ |
D | 16.67 ± 1.378▲∗ | 4.33 ± 0.762▲▲∗ | 8.25 ± 0.863▲▲∗∗ | 13.92 ± 1.270▲▲∗∗ |
E | 16.42 ± 1.234▲∗ | 3.42 ± 0.514▲▲∗ | 9.75 ± 1.162▲▲∗∗ | 14.50 ± 1.138▲▲∗∗∆ |
F | 15.67 ± 1.047▲∗ | 4.08 ± 0.468▲▲∗ | 6.92 ± 0.657▲▲∗∗ | 11.50 ± 1.019▲▲∗∗ |
Group A is the control group (male rabbit without any treatment); Group B is the dry eye model rabbit group; Group C is the dry eye rabbit model group treated with 1 mg/ml Buddleja officinalis Maxim eye drops; Group D is the dry eye rabbit model group treated with 1.5 mg/ml Buddleja officinalis Maxim eye drops; Group E is the dry eye rabbit model group treated with 3 mg/ml Buddleja officinalis Maxim eye drops; Group F is the dry eye rabbit group treated with testosterone. ▲▲P < 0.01 compared with Group A; ▲P > 0.05 compared with Group A; ∗∗P < 0.01 compared with Group B; ∗P > 0.05 compared with Group B; ∆∆P < 0.01 compared with Group F; ∆P > 0.05 compared with Group F.